On the afternoon of June 8, 2023, the "Anling Biomed (Shenzhen) GLP Center" officially commenced its operation. Anling Biomed, carrying the love and expectations of its customers, set sail to fulfill the expectations by providing quality services and expertise professional to its customers as well as society. The inauguration ceremony was conducted both online and offline.

The ceremony welcomed esteemed guests including Huang Ming, Director of the Shenzhen Pingshan District Science and Technology Innovation Bureau, Chen Song, Deputy Director of the Market Supervision and Regulation Bureau of Shenzhen Municipality; Ren Jin, senior II researcher and Director of drug safety evaluation and research team at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Zhang Xumu, Associate Dean of the College of Science and Foreign academician of the Russian Academy of Engineering; Zhang Jiancun, CEO and Founder of Henovcom Pharmaceuticals; Zhang Yingjun, Chairman and Senior Engineer of HEC Pharmaceuticals; Jin Yi, General Manager and Founder of Anling (Shenzhen); Li Ming, CEO, General Manager, and Founder of ZSHK; Qu Wei, Chief Technology Officer of ScienCare Pharmaceuticals; Xing Guozhen, Deputy General Manager and Founder of Anling (Shenzhen); and Zhang Kezhi, Founder and CEO of KG Pharma.

Guest speeches

Mr. Jin Yi, General Manager and founder of Anling Biomed (Shenzhen) Co.Ltd., delivered a welcome speech. As the head of the GLP institution, he expressed gratitude to the leaders and guests present at the event. He mentioned that the establishment of Anling Biomed (Shenzhen) GLP Center would not have been possible without the help and support of the government. Anling Biomed (Shenzhen) is a one-stop drug development service platform supported by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and the Pingshan District Government of Shenzhen. In the future, Anling Biomed (Shenzhen) will rely on its more than 20 years of industry experience to serve Pingshan and the Greater Bay Area, improve the biopharmaceutical industry chain in Pingshan and the Greater Bay Area, and inject new vitality into the development of the biopharmaceutical industry. Anling Biomed (Shenzhen) will provide high-quality services and work hand in hand with colleagues in the industry to contribute to the research and development of the biopharmaceutical industry.

Mr. Huang Ming, Director of the Shenzhen Pingshan District Science and Technology Innovation Bureau, congratulated the launch of Anling Biomed (Shenzhen) and expressed sincere wishes. He mentioned that Shenzhen is currently making every effort to build a biopharmaceutical characteristic park, fully implementing the service concept of "working together with enterprises and aiming for the same development direction," providing corresponding policy support and government services and other elements to enterprises, allowing them to take root and develop deeply here, and escorting the innovative development of the biopharmaceutical industry in the Greater Bay Area.

Academician Zhang Xumu, Associate Dean of the College of Science and Foreign academician of the Russian Academy of Engineering congratulated the launch of Anling (Shenzhen) and expressed gratitude to the organizers. He emphasized that since settling in Shenzhen, he has fully experienced the first-class business environment and regional investment environment here. He believes that with the participation of Anling (Shenzhen), it can leverage its GLP advantages to provide one-stop preclinical research services for new drugs, generic drugs, and medical devices, actively contributing to the development of the industry. He concluded by wishing Anling Biotech (Shenzhen) success in Shenzhen and a soaring future.

Dr. Zhang Jiancun, CEO and Founder of Henovcom Pharmaceuticals expressed his anticipation and congratulations for the official operation of Anling (Shenzhen) GLP. He believed that the addition of Anling (Shenzhen) would further enhance Anling's service capabilities in the biopharmaceutical industry chain, especially in the Guangdong-Hong Kong-Macao Greater Bay Area, injecting new energy and vitality into the innovative development of the biopharmaceutical industry in the Greater Bay Area.
Theme sharing 

Dr. Xing Guozhen, Deputy General Manager/Founder of Anling Biomed (Shenzhen), with the title of "The Importance of Non-clinical Drug Studies in the Evaluation of New Drugs”, He taking two famous drug safety incidents, the " Thalidomide" event and the clinical severe adverse reactions of Monoclonal antibody TGN1412 Phase I, as examples, the importance of safety evaluation research is illustrated.

 Non-clinical research serves as the precondition and foundation for new drugs entering clinical trials. Various aspects like design of initial clinical dosages, assessment risk, and substitute measures require non-clinical data support. Nonclinical pharmacokinetics and safety evaluation tests have a very clear set of available test batteries, in contrast to nonclinical pharmacodynamics, for which there are few standards.
 Clinical non-research runs through the entire new drug research and development process, which can not only provide basic/concept proof/pharmacokinetics/toxicology and other information, but also stop losses in drug research and development in a timely manner or provide a basis for new research and development ideas. 

Mr. Jin Yi, General Manager/Founder of Anling Biomed (Shenzhen), presented " A drug preclinical R&D service platform that meets global declarations--Progress and development of Amling Biomed GLP construction “in his speech title. Jin introduced Anling (Shenzhen)'s development history and service standards - meeting the requirements of AAALAC, CNAS, ICH, and GLP, thus conforming to international standards and providing a one-stop solution for drug non-clinical research, enabling global applications in China, the United States, and Europe.

Additionally, Jin also introduced Anling (Shenzhen)'s core team members, all of whom are professionals with experience from the Shanghai Institute of Materia Medica The. facility covers an area of 9,500 square meters, is equipped with a BSL-2 laboratory, can accommodate more than 30,000 small animals and 1,000 large animals, and has comprehensive quality management. 80% of the documentation system is electronic, and the computerized system is compliant, including an electronic system that meets the standards of the United States SEND declaration and possesses bilingual declaration capabilities in Chinese and English. The project's goal is to complete a formal IND project within the next 4 to 5 months, with modular project documentation and visualized processes.

Subsequently, Jin also discussed the layout of ZSHK Laboratories Limited International Biotechnology Group, which includes Anling (Suzhou) and Anling (Shenzhen), as well as a drug safety testing center jointly established with the Hong Kong Science Park, Hunan Experimental Dog Breeding and Research Base, and Guangxi Non-human Primate Breeding and Research Base

Finally, Jin wished for Anling to create brilliance together with Chinese pharmaceutical companies.

Roundtable discussion 

This roundtable forum was hosted by Dr. Li Ming, CEO/General Manager/Founder of ZSHK Laboratories Limited, with esteemed guests including Director Ren Jin, senior II researcher and Director of drug safety evaluation and research team at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences;Academician Zhang Xumu, Associate Dean of the College of Science
 and Foreign academician of the Russian Academy of Engineering; Dr. Zhang Jiancun, CEO and Founder of Henovcom Pharmaceuticals; Dr. Zhang Yingjun, Chairman and Senior Engineer of HEC Pharmaceuticals served as guests; Dr. Qu Wei, Chief Technology Officer of ScienCare Pharmaceuticals.
During the roundtable forum, the experts and scholars engaged in deep discussions and exchanges on the innovative in construction the pharmaceutical field, sharing their experiences and  insights

Dr. Zhang Jiancun proposed that RNA viruses are prone to mutation, and basic research in this field should be laid out in advance. Academician Zhang Xumu stated that innovative drugs are accumulated through continuous processes, and independent innovation should be adhered to firmly. Dr. Zhang Yingjun discussed the practical collaboration and ideas between pharmaceutical companies and research institutes. Dr. Qu Wei emphasized that medical innovation requires joint efforts from experts in various fields. Director Ren Jin summarized the preceding discussions, shared experiences in preclinical research, and raised higher expectations for the development of CRO companies.
The guests proposed feasible solutions and suggestions for the challenges and opportunities faced by the industry. This forum was acknowledged by the participating experts and scholars and provided a beneficial communication platform for promoting the development of medical innovation and advancing the industry.

Visiting session

Following the theme sharing sessions and roundtable discussions, the guests and attendees visited Anling (Shenzhen) to gain a comprehensive understanding of the related laboratories and services provided by Anling (Shenzhen).

Live discussion

The event was highly successful, and the guests and participants engaged in intense exchanges after the meeting. Once again, thank you to all the who professors participated online and offline for their strong support in this launching ceremony. See you at our next activity!